Jpmorgan Chase & CO Adma Biologics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 205,955 shares of ADMA stock, worth $4.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

205,955

Previous 239,588 14.04%

Holding current value

$4.4 Million

Previous $2.68 Million 53.73%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$11.21 - $20.03 $377,025 - $673,668	-33,633 Reduced 14.04%	205,955 $4.12 Million
Q2 2024 Aug 12, 2024	BUY	$5.98 - $11.18 $195,587 - $365,664	32,707 Added 15.81%	239,588 $2.68 Million
Q1 2024 May 10, 2024	BUY	$4.4 - $6.74 $90,257 - $138,257	20,513 Added 11.01%	206,881 $1.37 Million
Q4 2023 Feb 12, 2024	SELL	$3.08 - $4.52 $2,969 - $4,357	-964 Reduced 0.51%	186,368 $842,000
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $41,286 - $54,849	11,898 Added 6.78%	187,332 $670,000
Q2 2023 Aug 11, 2023	BUY	$3.12 - $4.22 $3,775 - $5,106	1,210 Added 0.69%	175,434 $647,000
Q1 2023 May 18, 2023	BUY	$3.01 - $3.87 $482,767 - $620,701	160,388 Added 1159.21%	174,224 $576,000
Q1 2023 May 11, 2023	SELL	$3.01 - $3.87 $815,926 - $1.05 Million	-271,072 Reduced 95.14%	13,836 $45,000
Q4 2022 Feb 13, 2023	BUY	$2.47 - $3.88 $432,032 - $678,658	174,912 Added 159.02%	284,908 $1.11 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $3,861 - $5,439	1,902 Added 1.76%	109,996 $268,000
Q2 2022 Aug 11, 2022	BUY	$1.43 - $2.2 $41,452 - $63,773	28,988 Added 36.64%	108,094 $214,000
Q1 2022 May 11, 2022	BUY	$1.28 - $1.83 $79,243 - $113,293	61,909 Added 360.0%	79,106 $144,000
Q4 2021 Feb 10, 2022	BUY	$1.09 - $1.66 $18,744 - $28,547	17,197 New	17,197 $24,000

Others Institutions Holding ADMA

# of Institutions

319

Shares Held

185M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $4.2B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Adma Biologics, Inc. Transaction History